Ironwood Pharmaceuticals - 53 Year Dividend History | IRWD
Historical dividend payout and yield for Ironwood Pharmaceuticals (IRWD) since 1971. The current TTM dividend payout for Ironwood Pharmaceuticals (IRWD) as of April 25, 2024 is $0.00. The current dividend yield for Ironwood Pharmaceuticals as of April 25, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Drug Manufacturing |
$1.268B |
$0.443B |
|
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
